摘要
目的探讨术前接受长春瑞滨联合表柔比星（VE）方案治疗的局部晚期乳腺癌的预后影响因素。方法回顾分析2001年9月至2006年5月术前接受3个周期VE方案化疗的119例局部晚期乳腺癌患者的临床病理资料。所有患者均经术前空心针活检证实为浸润性乳腺癌，新辅助化疗后接受手术治疗。术后根据新辅助化疗的临床疗效，再继续接受3个周期VE或标准的环磷酰胺＋表柔比星＋氟尿嘧啶（CEF）方案辅助化疗及局部区域放射治疗和相应的内分泌治疗。分析新辅助化疗前及术后临床病理资料与预后的关系。结果新辅助化疗后临床完全缓解27例（22．7％），部分缓解78例（65．5％）；肿瘤原发灶病理完全缓解（pCR）22例（18．5％）。本组115例（96．6％）获得随访，随访时间9-76个月，中位时间63．4个月。无局部复发转移患者共72例（60．5％）。5年无病生存率为58．7％，5年总生存率为71．3％。多因素分析显示，新辅助化疗前Ki-67（pre—Ki-67）高表达（P=0．012）、化疗后Ki-67（post—Ki-67）高表达（P=0．045）、化疗后病理未完全缓解（P=0．034）与无病生存时间的降低有关；pre—Ki-67高表达（P=0．017）、post—Ki-67高表达（P=0．001）、pre—ER阴性（P=0．002）、化疗后病理未完全缓解（P=0．034）与总生存时间的降低有关。结论pre—Ki-67、post—Ki-67及pre-ER的表达水平和新辅助化疗后肿瘤原发灶病理状况是接受术前3个周期VE新辅助化疗局部晚期乳腺癌的独立预后因素。
Objective To identify predictive markers of the long-term outcome for neo-adjuvant chemotherapy （NC） in locally advanced breast cancer （LABC） treated with intravenous vinorelbine （V） and epirubicin （E） combination regimen. Methods One hundred and nineteen patients with LABC were treated from September 2001 to May 2006. All patients were diagnosed as invasive breast cancer by 14G core needle biopsy and treated with three cycles of VE regimen before the operation. The patients were subjected to surgery and subsequently were given other three cycles of VE or cyelophosphamide ＋ epirubicin ＋ fluorouraeil （CEF） regimen according to the clinical responses. Local-regional radiotherapy was applied to all patients after the chemotherapy and followed by hormone-therapy according to hormone receptor status. The impact of clinical, pathological, and immunohistoehemical features on disease free survival （DFS） and overall survival （OS） was evaluated. Results All patients were evaluable for responses： clinical complete response was documented in 27 patients （22. 7% ）, 78 patients （65.5%） obtained partial clinical response. The pathological complete response was found in 22 cases （ 18. 5% ）. Of the patients, 115 eases （96. 6% ） were followed-up for a median time of 63.4 months （range, 9-76 months）, the 5-year DFS rate and OS rate was 58.7% and 71.3% , respectively. On multivariate analysis, high pre-Ki-67 （P = 0. 012） and post-Ki-67 expression （ P = 0. 045 ）, no pathological complete response after NC （ P = 0. 034 ） were associated with the higher risk of disease relapse ; high pre-Ki-67 （P = 0. 017） and post-Ki-67 expression （ P = 0. 001 ） , negative pre-ER （ P = 0. 002 ） and no pathological complete response after NC （ P = 0. 034 ） were associated with a shorter survival. Conclusion Pathological response in primary tumor, pre-Ki-67 and post-Ki-67 expression, pre-ER expression are important predictors of long-term outcome for LABC patients with thr
出处
《中华外科杂志》
CAS
CSCD
北大核心
2009年第7期511-515,共5页
Chinese Journal of Surgery
关键词
乳腺肿瘤
化学疗法
辅助
预后
长春瑞滨
表柔比星
Breast neoplasms
Chemotherapy, adjuvant
Prognosis
Vinorelbine
Epirubicin
